The obesity specialist says the drugs act on inflammation directly, not just through weight loss, and that benefits fade when patients stop taking them.
Recap by typeshit. Full story at Dermatology Times.
Fractyl plans to file a De Novo request with the FDA in late Q4, yet its shares closed about 63% lower that day over a class action and doubts about 12-month results.
Health records from 131 million adults linked GLP-1s to fewer dialysis or transplant cases. The researchers stress the study is observational and can't prove cause.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
18:20
Dr. Lindsay Ogle, an MD who covers metabolic health, talks through options for people whose appetite hasn't settled on GLP-1 treatment.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
Adults coming off GLP-1 drugs who got a wellness app or medically tailored meals regained about 7% less weight than usual care, in a small trial of 39 people.
Loading…